Palobiofarma has started the clinical development of PBF-1650, a novel treatment of autoimmune diseases, like NASH and psoriasis. The “first in human” study will take place at the University Clinic of Navarre (CUN). PBF-1650 will be the program number six with which the company is able to initiate clinical development, demonstrating the outstanding productivity of its discovery platform. The company plans to start an additional Phase I study with a novel compound this year, in addition to the two Phase II compounds (PBF-677 and PBF-680) and the broad Oncology franchise composed by three programs (PBF-509, licensed to Novartis, PBF-1129 and PBF-999).
Palobiofarma has started the clinical development of PBF-1650
Recent News
- Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
- Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain
- PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.